Inflammation and lipid regulator with UBA-like and NBR1-like domains protein (ILRUN)

The **Inflammation and lipid regulator with UBA-like and NBR1-like domains protein** (ILRUN) is a multifunctional protein encoded by the *ILRUN* (formerly *C6orf106*) gene[1][3]. ILRUN contains an N-terminal ubiquitin-associated (UBA)-like domain and a region similar to NBR1, which enable it to bind ubiquitinated proteins and regulate the stability and function of transcription factors such as PPARα—thus influencing hepatic lipoprotein production and lipid metabolism[1][2]. ILRUN is also highly expressed in various immune cell types, including macrophages, and acts as a negative regulator of the immune response, notably by suppressing cytokine production through controlling the binding and activity of transcription factors like IRF3[3]. Genetic associations and animal studies identify ILRUN as a pro-atherogenic factor, promoting the progression of atherosclerosis via both lipid-dependent and non-lipid-dependent (e.g., inhibition of efferocytosis) mechanisms[1][2]. Variants in the ILRUN locus are linked to increased risk of cardiovascular and metabolic diseases, as well as roles in cancer, infection, and inflammation[2][3]. No approved drugs are known to modulate ILRUN directly, but it remains a novel therapeutic target under preclinical investigation.

Other names

ILRUNC6orf106FLJ22195dJ391O22.4FP852uncharacterized protein C6orf106

Not a current drug target; no approved drugs directly target ILRUN as of the latest research. Mechanistic studies show it acts by regulating transcription factors and ubiquitinated protein turnover[1][2][3].